Skip to content

Inflammatory eye disease: Pre-treatment assessment of patients prior to commencing immunosuppressive and biologic therapy: Recommendations from an expert committee

Research output: Contribution to journalReview article

  • Denis Wakefield
  • Peter McCluskey
  • Gerhild Wildner
  • Stephan Thurau
  • Gregory Carr
  • Soon Phaik Chee
  • John Forrester
  • Andrew Dick
  • Bernard Hudson
  • Susan Lightman
  • Justine Smith
  • Ilknur Tugal-Tutkun
  • on behalf of the pre-treatment assessment Review panel
Original languageEnglish
Pages (from-to)213-222
Number of pages10
JournalAutoimmunity Reviews
Volume16
Issue number3
Early online date27 Jan 2017
DOIs
DateAccepted/In press - 25 Oct 2016
DateE-pub ahead of print - 27 Jan 2017
DatePublished (current) - 1 Mar 2017

Abstract

Aim To outline recommendations from an expert committee on the assessment and investigation of patients with severe inflammatory eye disease commencing immunosuppressive and/or biologic therapy.

Method The approach to assessment is based on the clinical experience of an expert committee and a review of the literature with regard to corticosteroids, immunosuppressive drug and biologic therapy and other adjunct therapy in the management of patients with severe sight-threatening inflammatory eye disease.

Conclusion We recommend a careful assessment and consultative approach by ophthalmologists or physicians experienced in the use of immunosuppressive agents for all patients commencing immunosuppressive and/or biologic therapy for sight threatening inflammatory eye disease with the aim of preventing infection, cardiovascular, metabolic and bone disease and reducing iatrogenic side effects.

    Research areas

  • Biologicals, Evaluation, Immunosuppression, Therapy, Uveitis

Download statistics

No data available

Documents

Documents

  • Full-text PDF (abstract)

    Rights statement: This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at http://www.sciencedirect.com/science/article/pii/S1568997217300137 . Please refer to any applicable terms of use of the publisher.

    Accepted author manuscript, 88 KB, PDF document

    Licence: CC BY-NC-ND

  • Full-text PDF (accepted author manuscript)

    Rights statement: This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Elsevier at http://www.sciencedirect.com/science/article/pii/S1568997217300137 . Please refer to any applicable terms of use of the publisher.

    Accepted author manuscript, 255 KB, PDF document

    Licence: CC BY-NC-ND

DOI

View research connections

Related faculties, schools or groups